Evidence map›Paper›PMID 42396486›Full record

ArticleResearch square2026

Sparse-Observation Multi-Horizon Glaucoma Progression Forecasting with Biologically Constrained Temporal Consistency: A Glaucoma Case Study.

Mousa Moradi, Jerry Cao-Xue, Asahi Fujita, Daniel L Liebman, Alessandro Jammal, Mengyu Wang, Tobias Elze, Mohammad Eslami, Nazlee Zebardast

Abstract readPreprint
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mousa MoradiHarvard Ophthalmology AI Lab, Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, United States.ORCID 0000-0002-0020-7365
Jerry Cao-XueHarvard Ophthalmology AI Lab, Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, United States.ORCID 0009-0005-0263-9937
Asahi FujitaMassachusetts Eye and Ear, Harvard Medical School, Boston, MA, United States.ORCID 0000-0003-2251-4363
Daniel L LiebmanMassachusetts Eye and Ear, Harvard Medical School, Boston, MA, United States.
Alessandro JammalMassachusetts Eye and Ear, Harvard Medical School, Boston, MA, United States.ORCID 0000-0001-5341-8353
Mengyu WangHarvard Ophthalmology AI Lab, Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, United States.
Tobias ElzeHarvard Ophthalmology AI Lab, Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, United States.ORCID 0000-0002-2032-0496
Mohammad EslamiHarvard Ophthalmology AI Lab, Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, United States.ORCID 0000-0002-6570-2826
Nazlee ZebardastMassachusetts Eye and Ear, Harvard Medical School, Boston, MA, United States.ORCID 0000-0003-1763-9401

Funding

VISION RESEARCHP30EY003790 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Patricia Ann D'Amore · 1985 to 2026
$25.5M
Personalizing Glaucoma Diagnosis by Disease Specific Patterns and Individual Eye AnatomyR01EY030575 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI ELZE, TOBIAS · 2019 to 2023
$2.4M
Enhancing Glaucoma Risk Prediction through Advanced Genomics and Machine LearningR01EY036518 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI Nazlee Zebardast · 2024 to 2026
$2.0M
NEI NIH HHS P30 EY003790NEI NIH HHS R01 EY030575NEI NIH HHS R01 EY036518
6 · The paper itself

Abstract

Glaucoma progression forecasting from sparse longitudinal data remains unsolved, as existing models require dense multi-year inputs and lack the biological constraints. We introduce a sparse-observation framework that predicts multi-horizon outcomes from only two visits, incorporating a novel TCMH (Temporally Consistent Multi-Horizon) loss that enforces monotonic risk ordering to reflect irreversible disease biology. Applied to glaucoma progression, we integrate circumpapillary retinal nerve fiber layer (cpRNFL) images, visual field total deviation (VFTD) maps, and clinical covariates through ConvNeXt architecture trained with TCMH loss. In 3,593 patients (13,087 sequences), our model achieved AUROC 0.968 and accuracy 0.947 for two-, three-, and four-year progression forecasting, with 10.2% better calibration than baseline and 0.0163 maximum demographic disparity. At 90% coverage, classification error remained 2.5%, enabling automated risk stratification with expert review for only uncertain cases. The model exceeded three independent specialist graders on specificity (0.98 vs. 0.57-0.73) on 108 held-out eyes. These results establish sparse-observation temporally consistent forecasting as a generalizable paradigm for calibrated long-horizon risk prediction in irreversible progressive diseases.

Indexed as

cpRNFLGlaucoma progressionMulti-horizonTemporal consistencyVFTD

Identifiers

PMID42396486
PMCPMC13321340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.